Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly CJC-1134-PC injection in drug-naïve type 2 diabetes mellitus – Phase III, randomized, double-blind, placebo-controlled trial
CTR20202681Phase 3Completed
- Sponsor
- Changshan Biochemical Pharmaceutical
- Start
- Jan 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of albenatide in type 2 diabetes mellitus (T2DM), sponsored by Changshan Biochemical Pharmaceutical. Started Jan 2021; status: completed.
02
Drugs
albenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20202681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202681.